Skip to content

Smoking Habits and Smoking Cessation in Young Adults

Smoking Cessation in Young Adults in Northern Finland

Status
Completed
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01531049
Enrollment
300
Registered
2012-02-10
Start date
2012-05-31
Completion date
2016-09-02
Last updated
2017-06-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Habits, Smoking, Smoking Cessation

Keywords

smoking cessation, young adults, motivational counselling, smoking, nicotine replacement therapy, therapy

Brief summary

The purpose of this study is to assess the efficacy and effectiveness of varenicline and nicotine patch combined with motivational interview technique in smoking cessation of young adults over 12 months follow-up.

Detailed description

Most teenage smokers are still smoking when they become adults confirming that stopping of smoking at young age is difficult although majority of young smokers want to quit. Young smokers experience many relapses partly due to the lack of appropriate and available cessation services. The discomfort experienced during cessation attempts is likely to be negatively associated with cessation success. Quitting of smoking is by the far most important procedure in preventing COPD progression. In Finland, 18-35% of young adults smoke, the variability being associated at least with socioeconomic background, education and geographical area. Our recent studies on male military draftees have shown that smoking is much more frequent in Northern than Southern Finland. However young men want to quit and accept new smoking restrictions. Very few studies are available on quitting attempts or counselling, pharmacotherapy and/or their combinations in young adults who want to quit.

Interventions

DRUGvarenicline

days 1.-3 0,5mgx1/day, days 4.-7 0,5mgx2/day, day 8 to the 12weeks 1mgx2 /day

DRUGNicotine cutaneous patch 15mg/16h

One patch for 16hours/day and duration of 8 weeks.

DRUGNicotine cutaneous patch 10mg/16h

One patch 16hours/day and duration of 8 weeks

OTHERPlacebo cutaneous patch

No active medication.O ne patch 16hours and duration for 8 weeks

Sponsors

University of Oulu
CollaboratorOTHER
University of Helsinki
CollaboratorOTHER
Tuula Toljamo
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 26 Years
Healthy volunteers
Yes

Inclusion criteria

* healthy daily smokers * a daily smoker has smoked at least 1cig/day every day during last month and has smoked at least 100 cig ever * a nonsmoker has smoked less than 50 cig ever,and has not smoked at all during last month * motivated to quit smoking and ready to 12 months follow-up * minor allergy or mild asthma without regular medication is allowed

Exclusion criteria

* any chronic disease with daily medication * known allergy to study medications(varenicline, nicotine patch,nicotine gum) * any substance and/or alcohol abuse * drop-outs are counted as current smokers

Design outcomes

Primary

MeasureTime frame
The abstinence rate3 months follow-up

Secondary

MeasureTime frame
The saliva cotinine verified abstinence rate3 months follow-up
The abstinence rate1, 6 and 12 months follow-up

Countries

Finland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026